Abstract 17341: The Impact of Intravenous Ferric Carboxymaltose on Renal Function: An Analysis of the FAIR-HF Study
Background: Renal dysfunction commonly complicates the natural course of chronic heart failure (CHF) and predicts poor outcome. Currently applied CHF therapies have either no effect on, or even worsen renal function. The FAIR-HF study demonstrated that treatment with intravenous ferric carboxymaltose (FCM) in iron deficient CHF patients is well tolerated and improves symptoms and quality of life. We report here the results of the FAIR-HF analysis designed to assess the effects of FCM on renal function.
Methods: We enrolled 459 CHF patients (NYHA class II-III, LVEF 32%) with iron deficiency (ferritin <100 μg/L, or 300 μg/L if transferrin saturation <20%); 304 patients were randomly assigned to FCM and 155 to placebo; treatment was continued for 24 weeks. Renal function was assessed at baseline and at Week 4, 12 and 24 visits, either by measurement of serum creatinine, or as estimated glomerular filtration rate (eGFR) using the MDRD formula.
Results: At baseline, renal function did not differ between groups (63.8±21.2 vs 64.8±25.3 ml/min/1.73m2, FCM vs placebo). Treatment with FCM was associated with an improvement in renal function (table) across the whole spectrum of CHF patients (p>0.2 for interaction with baseline renal function, age, sex, CHF severity, underlying CHF etiology, presence of anemia). Additionally, more patients in the FCM group demonstrated an eGFR improvement of 5ml/min/1.73m2 (week 4: 38% vs 34%, week 12: 33% vs 26%, week 24: 35% vs 25%, FCM vs placebo respectively).
Conclusions: Correction of iron deficiency with intravenous FCM in CHF patients was associated with an improvement in renal function.
- © 2010 by American Heart Association, Inc.